RTTNews BiotechCodex · 实盘不做把握 6/10
北京时间·🕒 发布 22:04:45时区推断·⟳ 抓取 22:15:22·⚡ 决策 07-28 22:16:29 +1m07s·90.8 天前
Cipla 获 FDA 批准三种规格仿制 Advair Diskus
FDA 批准的是 Cipla 的复杂吸入制剂里程碑，但 Advair Diskus 美国市场已有 Mylan、Hikma、Teva 等仿制竞争者，并非独家首仿。
📄 原文RTTNews Biotech↗ 原文
Cipla Receives FDA Approval For Generic Advair Diskus In All Strengths
Cipla Limited (CIPLA) announced that the U.S. FDA has approved its Abbreviated New Drug Application (ANDA) for the gene…
不做 Cipla（CIPLA.IN）
Cipla 主股在印度市场不属本系统常用可执行市场；且该仿制 Advair 批准已有竞争者、卖方预期已纳入，短线新增 edge 不足。
不做 GSK（GSK.US）
新增 Cipla 仿制竞争对 GSK 的 Advair 存量收入影响不够直接且品类已有多家仿制药，不构成可执行做空。
不做 Teva Pharmaceutical（TEVA.US）
Cipla 获批会增加仿制 Advair 竞争，但相对 Teva 总体业务量级太小，无法形成同向短线交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- RTTNews 报道 Cipla ANDA 获 FDA 批准，覆盖 Advair Diskus 三种规格，引用 IQVIA 约 9.08 亿美元市场规模。市场反应:报道正文称 Cipla 周二收于 INR 1444.60，涨 2.50%。
- ICICI Direct 确认该批准，并称 Generic Advair 对 Cipla FY27 美国呼吸管线有意义，但其估算已纳入 H1FY27 贡献。市场反应:页面显示 CIPLA 约 1409，日内 -0.09%。
- Drugs.com 列示 Advair Diskus 早已有 Mylan、Hikma、Teva 等 FDA 批准仿制版本，说明 Cipla 获批不是无竞争首仿。
关键理由
- FDA 批准的是 Cipla 的复杂吸入制剂里程碑，但 Advair Diskus 美国市场已有 Mylan、Hikma、Teva 等仿制竞争者，并非独家首仿。
- IQVIA 口径美国市场约 9.08 亿美元，ICICI Direct 明确称其已在 FY27 美国呼吸管线估算中纳入，新增预期差有限。
- Cipla 主要上市交易在印度市场，不在本系统常用可执行市场范围；对 GSK/Teva/Hikma 等存量竞争者的短线负面传导也过小。
主要风险
- 若后续 Cipla 披露上市节奏、份额或利润率明显高于卖方预期，需重新评估印度本地股的可交易性。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-28 · 影响 weakens
ICICI Direct 表示其估算已经纳入 Generic Advair 在 H1FY27 的贡献，削弱追多预期差。
检索:Cipla generic Advair approval already factored estimates FY27 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-06-11 · 影响 weakens
已有多家公司拥有 Advair Diskus 仿制版本，Cipla 新增获批的商业增量需面对存量竞争。
检索:generic Advair Diskus approved manufacturers Mylan Hikma Teva 原文 ↗
原文全文
展开原文 · 2,062 字
Cipla Limited (CIPLA) announced that the U.S. FDA has approved its Abbreviated New Drug Application (ANDA) for the generic version of Advair across all three strengths—100/50 mcg, 250/50 mcg, and 500/50 mcg.
Advair Diskus (fluticasone propionate and salmeterol inhalation powder) is a widely prescribed combination therapy for asthma and chronic obstructive pulmonary disease (COPD). Cipla's product is a therapeutically equivalent version, offering patients a lower-cost alternative in a U.S. market estimated at $908 million, according to IQVIA.
This approval marks Cipla's first dry powder inhaler (DPI) approval from its U.S. manufacturing network, representing a significant milestone in the company's expansion of complex respiratory capabilities in the United States.
Achin Gupta, Managing Director & Global CEO, Cipla, said the approval reinforces the company's commitment to expanding access to complex therapies in the U.S. and highlights its strength in scaling sophisticated inhalation products through integrated capabilities.
Marc Falkin, Chief Executive Officer, of Cipla North America added, that the approval reflects targeted investments in differentiated inhalation manufacturing and strengthens Cipla's ability to provide reliable, high-quality supply in a competitive category.
This FDA approval underscores Cipla's growing presence in the U.S. generics market and its long-standing expertise in respiratory care.
CIPLA has traded between INR 1,165.70 and INR 1,673.00 over the past year. The stock closed Tuesday's trading at INR 1,444.60, up 2.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
Advair Diskus (fluticasone propionate and salmeterol inhalation powder) is a widely prescribed combination therapy for asthma and chronic obstructive pulmonary disease (COPD). Cipla's product is a therapeutically equivalent version, offering patients a lower-cost alternative in a U.S. market estimated at $908 million, according to IQVIA.
This approval marks Cipla's first dry powder inhaler (DPI) approval from its U.S. manufacturing network, representing a significant milestone in the company's expansion of complex respiratory capabilities in the United States.
Achin Gupta, Managing Director & Global CEO, Cipla, said the approval reinforces the company's commitment to expanding access to complex therapies in the U.S. and highlights its strength in scaling sophisticated inhalation products through integrated capabilities.
Marc Falkin, Chief Executive Officer, of Cipla North America added, that the approval reflects targeted investments in differentiated inhalation manufacturing and strengthens Cipla's ability to provide reliable, high-quality supply in a competitive category.
This FDA approval underscores Cipla's growing presence in the U.S. generics market and its long-standing expertise in respiratory care.
CIPLA has traded between INR 1,165.70 and INR 1,673.00 over the past year. The stock closed Tuesday's trading at INR 1,444.60, up 2.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 25, 2026 02:46 ET The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。